New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 19, 2012
06:14 EDTSTD, RIMM, JNJ, DOW, CS, BCS, AEG, UBS, DB, RY, BBVA, LYG, ING, RBS, JPMOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: Europe's program to defuse its financial crisis by injecting cash into the banking system is running out of energy as interest rates rise and some banks have little cash left, the Wall Street Journal reports...Dow Chemical (DOW) and other chemical companies see new opportunities in the enormous domestic deposits of gas, the Wall Street Journal reports...REUTERS: U.S. coal exports to China could more than double to over 12M tons in 2012 due to depressed freight rates and a decline in U.S. demand, says Xcoal Energy & Resources CEO Thrasher, Reuters reports...Johnson & Johnson (JNJ) received EU clearance to purchase Swiss medical device maker Synthes for about $21B, Reuters reports...BLOOMBERG: Research In Motion (RIMM) is close to deciding on a financial adviser, and JPMorgan Chase (JPM) is said to be the leading candidate to help the company weigh strategy options, Bloomberg reports.
News For STD;RBS;ING;LYG;BBVA;RY;DB;UBS;AEG;BCS;CS;DOW;JNJ;RIMM;JPM From The Last 14 Days
Check below for free stories on STD;RBS;ING;LYG;BBVA;RY;DB;UBS;AEG;BCS;CS;DOW;JNJ;RIMM;JPM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
July 14, 2014
15:19 EDTJNJ Johnson & Johnson July 105 straddle priced for 1.6% move into Q2
14:40 EDTJPMJPMorgan July 56.5 straddle priced for 2.2% move into Q2
Subscribe for More Information
14:27 EDTJNJEarnings Preview: J&J pharmaceutical sales expected to drive Q2
Johnson & Johnson (JNJ) is scheduled to report second quarter earnings before the market open on Tuesday, July 15, with a conference call scheduled for 8:30 am ET. Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. EXPECTATIONS: Analysts are looking for earnings per share of $1.55 on revenue of $18.94B, according to First Call. The consensus range for EPS is $1.45-$1.61 on revenue of $18.55B-$19.30B. LAST QUARTER: Johnson & Johnson reported first quarter EPS of $1.54 against estimates of $1.48 on revenue of $18.1B against estimates of $18B. The drug maker raised its fiscal year EPS view to $5.80-$5.90 against a consensus estimate of $5.83. J&J noted a 3.2% decrease in worldwide consumer sales in Q1 but saw a 10.8% increase in worldwide pharmaceutical sales. Primary contributors to operational sales growth in Q1 pharmaceutical sales were Stelara, Invega, Sustenna/Xeplion, Prezista, Velcade and sales of new products. Pharmaceutical sales results were negatively impacted by loss of exclusivity for Aciphex, a proton pump inhibitor for gastrointestinal disorders and Concerta for the treatment of attention deficit hyperactivity disorder. STREET RESEARCH: On July 14, RBC Capital raised its Q2 estimates for Johnson & Johnson to reflect the firm's outlook for higher pharmaceutical sales by the company. The firm raised its price target on the shares to $110 from $106 and kept an Outperform rating on the stock. PRICE ACTION: Shares of Johnson & Johnson are up approximately 8.5% since its last earnings report, and are trading near flat in afternoon trading.
12:24 EDTJNJJohnson & Johnson technical notes before earnings
The company is scheduled to report before market open on July 15th. The shares in the prior three months have risen by more than 8%, anticipating positive news for the current and forthcoming quarters. At the current price of $105.39, the only remaining established resistance on the daily chart is at the life high of $106.74. If the news and guidance is better than expected, a run to $110, or $115 at an extreme, would be possible. If the news fails to meet expectations or guidance is weak, support would be at $102.70, the 50-day moving average. A break below this uptrend support proxy would be a sell signal in many technical trading systems and would break an uptrend in place since early March of this year. On a sliding scale of increasingly weaker news, supports would next be at $99.96, and then at $96.87.
08:30 EDTJNJJohnson & Johnson should be bought on any weakness, says RBC Capital
Subscribe for More Information
08:01 EDTJPMJP Morgan July volatility increases into Q2 and outlook
Subscribe for More Information
07:20 EDTDOWControlled Released Society to hold annual meeting
Subscribe for More Information
07:13 EDTBCSDark pool investigation ups pressure on Barclays head, Reuters says
Barclays head Antony Jenkins is up one of biggest tests of his leadership when he chooses whether the firm should fight accusations that it deceived and defrauded U.S. clients, reported Reuters. If Jenkins accepts the allegations, he will have to deal with a problem arising from his promise to jettison any business that does not fit into the firm's new unblemished image. Reference Link
July 11, 2014
15:47 EDTBCSBarclays index unit could sell for close to $1B, Reuters reports
Subscribe for More Information
07:36 EDTJNJJohnson & Johnson Q2 EPS likely to exceed expectations, says Bernstein
Subscribe for More Information
07:30 EDTBCSBarclays to re-purpose cashiers with more customer-focused role, FT says
Barclays plans to have its 6,500 cashiers change their positions away from processing simple transactions and turning more toward giving customers advice, said Financial Times, which noted that the bank will give those employees an automatic 2.8% annual pay raise from October. Reference Link
07:20 EDTJPMBig banks seen losing reserve release cushion, Reuters says
Releasing loan-loss reserves has helped U.S. big banks weather a period of weak loan demand and lower fee income, but Q2 results from the banks may see less benefit from the practice as loss rates and reserves near their lower limits, said Reuters. Publicly traded companies in the space include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
06:48 EDTBCS, RBS, LYGBank of England says banks' capital requirement could rise, Reuters reports
Subscribe for More Information
July 10, 2014
07:08 EDTDB, UBS, ING, BCS, LYG, CS, RBSECB keeps tight grip on banks with health check results, Reuters says
The European Central Bank is targeting to keep a tight grip banks in the final phase of a balance sheet health check in October, giving them only 48 hours to review the test results before publishing them, according to Reuters, citing two people familiar with the matter. The assessment will look into banks’ balance sheets and measure their ability to handle shock and stress. Publicly traded European banks include Banco Santander (SAN), Barclays (BCS), Credit Suisse (CS), Deutsche Bank (DB), HSBC (HSBC), ING Groep (ING), Lloyds Banking (LYG), Royal Bank of Scotland (RBS) and UBS (UBS).
06:52 EDTBCSGoldman gains energy marketer Golender from Barclays, Reuters says
Goldman Sachs (GS) appointed oil marketer Roy Golender as vice president of energy sales from Barclays (BCS), according to Reuters citing a company spokesman. Golender's LinkedIn profile says that while at Barclays Golender spent four years in commodity derivatives sales. Reference Link
06:45 EDTCSCredit Suisse asks sentencing for aiding tax evasion be delayed, WSJ reports
Subscribe for More Information
06:21 EDTJPM, UBSJPMorgan appoints Li as new China head, Reuters says
JPMorgan Chase (JPM) said it has appointed former UBS (UBS) banker David Li as the new head of its China division to replace top China banker Fang Fang who left the firm in March, according to Reuters, citing a statement from the U.S. company. Reference Link
July 9, 2014
10:34 EDTLYGLloyds Banking to cut 500 jobs in finance, retail, Daily Telegraph reports
Subscribe for More Information
10:02 EDTDBOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
05:48 EDTDBDeutsche Bank upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded JPMorgan to Overweight citing a favorable risk/reward following the bank's capital increase.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use